Search Prime Grants

U01DA053054

Cooperative Agreement

Overview

Grant Description
Therapeutic agent for rapid reversal of methamphetamine intoxication.
Awardee
Clear Scientific
Funding Goals
TO SUPPORT BASIC AND CLINICAL NEUROSCIENCE, BIOMEDICAL, BEHAVIORAL AND SOCIAL SCIENCE, EPIDEMIOLOGIC, HEALTH SERVICES AND HEALTH DISPARITY RESEARCH. TO DEVELOP NEW KNOWLEDGE AND APPROACHES RELATED TO THE PREVENTION, DIAGNOSIS, TREATMENT, ETIOLOGY, AND CONSEQUENCES OF DRUG ABUSE AND ADDICTION, INCLUDING HIV/AIDS. TO SUPPORT RESEARCH TRAINING AND RESEARCH SCIENTIST DEVELOPMENT. TO SUPPORT DISSEMINATION OF RESEARCH FINDINGS. SMALL BUSINESS INNOVATION RESEARCH (SBIR) LEGISLATION IS INTENDED TO EXPAND AND IMPROVE THE SBIR PROGRAMS TO EMPHASIZE AND INCREASE PRIVATE SECTOR COMMERCIALIZATION OF TECHNOLOGY DEVELOPED THROUGH FEDERAL SBIR RESEARCH AND DEVELOPMENT, INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN THE SBIR PROGRAM. THE LEGISLATION INTENDS THAT THE SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION.
Grant Program (CFDA)
93.279 - Drug Abuse and Addiction Research Programs
Awarding / Funding Agency
National Institute on Drug Abuse (NIDA) [HHS - NIH]
Place of Performance
Massachusetts United States
Geographic Scope
State-Wide
Related Opportunity
Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional) (PAR-19-327)
Analysis Notes
Amendment Since initial award the End Date has been extended from 05/31/23 to 05/31/24 and the total obligations have increased 207% from $3,932,236 to $12,056,183.
Clear Scientific was awarded Therapeutic Agent for Rapid Reversal of Methamphetamine Intoxication Cooperative Agreement U01DA053054 worth $12,056,183 from National Institute on Drug Abuse in September 2020 with work to be completed primarily in Massachusetts United States. The grant has a duration of 3 years 8 months and was awarded through assistance program 93.279 Drug Abuse and Addiction Research Programs. The Cooperative Agreement was awarded through grant opportunity Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional).

Status
(Complete)

Last Modified 12/17/24

Period of Performance
9/30/20
Start Date
5/31/24
End Date
100% Complete

Funding Split
$12.1M
Federal Obligation
$0.0
Non-Federal Obligation
$12.1M
Total Obligated
100.0% Federal Funding
0.0% Non-Federal Funding

Activity Timeline

Interactive chart of timeline of amendments to U01DA053054

Transaction History

Modifications to U01DA053054

Additional Detail

Award ID FAIN
U01DA053054
SAI Number
U01DA053054-366901961
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Small Business
Awarding Office
75N600 NIH NATIONAL INSITUTE ON DRUG ABUSE
Funding Office
75N600 NIH NATIONAL INSITUTE ON DRUG ABUSE
Awardee UEI
USCME5Z4GVN7
Awardee CAGE
7NXK8
Performance District
MA-90
Senators
Edward Markey
Elizabeth Warren

Budget Funding

Federal Account Budget Subfunction Object Class Total Percentage
National Institute on Drug Abuse, National Institutes of Health, Health and Human Services (075-0893) Health research and training Grants, subsidies, and contributions (41.0) $7,999,464 100%
Modified: 12/17/24